CN Patent

CN1717253A — 固体制剂

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2006-01-04 · 20y expired

What this patent protects

本文提供了含有胰岛素耐受性改善药物和(除胰岛素耐受性改善药物之外的)活性成分的固体制剂，该固体制剂用作糖尿病等的治疗药物，并且具有优异的胰岛素耐受性改善药物和(除胰岛素耐受性改善药物之外的)活性成分含量均匀性、以及优异的诸如溶出性和制剂硬度的制剂特性。

USPTO Abstract

本文提供了含有胰岛素耐受性改善药物和(除胰岛素耐受性改善药物之外的)活性成分的固体制剂，该固体制剂用作糖尿病等的治疗药物，并且具有优异的胰岛素耐受性改善药物和(除胰岛素耐受性改善药物之外的)活性成分含量均匀性、以及优异的诸如溶出性和制剂硬度的制剂特性。

Drugs covered by this patent

metformin-hydrochloride (METFORMIN HYDROCHLORIDE)

Patent Metadata

Patent number: CN1717253A
Jurisdiction: CN
Classification: —
Expires: 2006-01-04
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.